Business
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event.\nCAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced it will host an investor conference at its U.S. office in Cambridge, Massachusetts on Monday, July 24, 2023 from 8:30 AM- 10:15 AM.\n \n \nNeuroSense's CEO, Alon Ben-Noon, VP of R&D, Dr. Shiran Zimri, and VP Business Development, Nedira Salzman-Frenkel, will present to investors and analysts, followed by a Q&A. The presentation will focus on NeuroSense's scientific advances, its Phase 2b amyotrophic lateral sclerosis (ALS) clinical trial design and endpoint analysis, upcoming catalysts, the Company's strategy, and potential future partnerships.\nThe Phase 2b (PARADIGM) clinical trial has completed enrollment and topline results are expected Q4 2023. 96% of participants who completed the 6-month double-blind phase of the trial chose to join the 12-month open-label extension, wherein all participants are being treated with NeuroSense's lead therapeutic product for ALS, PrimeC.\nInvestors interested in attending the invitation-only event may view the agenda and request to attend via the LinkedIn event page or RSVP via email: [email protected] and await confirmation and further details.\nAbout NeuroSense\nNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.\nFor additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.\nForward-Looking Statements\nThis press release...